TheraRadar
← Back
Data updated: Mar 29, 2026

SEAGEN

OncologyGastroenterologyImmunology
Biotech

SEAGEN is a biotechnology company focused on Oncology, Gastroenterology, Immunology. Key products include TUKYSA.

2020
Since
2
Drugs
-
Trials
2
Approved (2yr)

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 87%
2 drugs Phase 3: 8 Phase 2: 22 Phase 1: 28
Gastroenterology 11%
0 drugs Phase 2: 4 Phase 1: 6
Immunology 2%
0 drugs Phase 2: 1 Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...